CA125, Human (HEK293, His)

CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells[1][2][3][4][5][6][7].

GFTHWIPVPT SSTPGTSTVD LGSGTPSSLP SPTTAGPLLV PFTLNFTITN LKYEEDMHCP GSRKFNTTER VLQSLLGPMF KNTSVGPLYS GCRLTLLRSE KDGAATGVDA ICTHRLDPKS PGVDREQLYW ELSQLTNGIK ELGPYTLDRN SLYVNGFTHQ TSAPNTSTPG TSTVDLGTSG TPSSLPSPTS AGPLLVPFTL NFTITNLQYE EDMHHPGSRK FNTTERVLQG LLGPMFKNTS VGLLYSGCRL TLLRPEKNGA ATGMHHHHHH

[1]Claudia Seelenmeyer, et al. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci. 2003 Apr 1;116(Pt 7):1305-18.|[2]Jacobs I,et al. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1-12.|[3]Plana A, et al. Radiologically enlarged cardiophrenic lymph nodes and CA-125 in relation to diaphragmatic carcinomatosis, surgical outcome, and overall survival in advanced ovarian cancer. Acta Oncol. 2023 May;62(5):451-457.|[4]Zhang R, et al. Molecular Biomarkers for the Early Detection of Ovarian Cancer. Int J Mol Sci. 2022 Oct 10;23(19):12041. |[5]Yamashita T, et al. Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer. Am J Pathol. 2023 Mar;193(3):350-361. |[6]Kobayashi H, et al. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol Immunother. 1993 Aug;37(3):143-9. |[7]Saga T, et al. An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies[J]. Japanese journal of cancer research, 1990, 81(11): 1141-1148.